Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Conditions: Diffuse Astrocytoma, IDH-Mutant; Glioblastoma, IDH-wildtype; Brain Metastases, Adult; Cervical Cancer; Colorectal Cancer; Esophageal Cancer; Esophageal Squamous Cell Carcinoma; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Head and Neck Squamous Cell Carcinoma; Melanoma; Merkel Cell Carcinoma; Microsatellite Instability-High Solid Malignant Tumor; Mismatch Repair Deficient Solid Malignant Tumor; Microsatellite Instability-High Colorectal Cancer; Mismatch Repair Deficient Colorectal Cancer; Non-small Cell Lung Cancer; Renal Cell Carcinoma; Small Cell Lung Cancer; Squamous Cell Carcinoma; Urothelial Carcinoma

Interventions: Drug: NEO212 Oral Capsule; Drug: Ipilimumab; Drug: Pembrolizumab; Drug: Nivolumab; Drug: Regorafenib; Drug: Carboplatin; Drug: Paclitaxel; Drug: FOLFIRI Protocol; Drug: Bevacizumab

Sponsors: Neonc Technologies, Inc.

**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

December 6, 2023Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments